<h1 itemprop="aspect"> <strong>Darbepoetin Alpha Side Effects</strong></h1><div class="thumbnail-div"> <img width="84" height="84" src="http://www.bad-drug.net/wp-content/uploads/2013/01/Darbepoetin-Alpha-84x84.jpg?1df917" class="attachment-84x84 wp-post-image" alt="Darbepoetin Alpha" title="Darbepoetin Alpha" pagespeed_url_hash="1572360132" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></div><h2>Serious Adverse Side Effects</h2> <b>Darbepoetin Alpha</b> has some very serious adverse side effects associated with it.  These include:<ul><li>Cardiovascular side effects like congestive heart failure, disorders of the cardiovascular system, high blood pressure and acute heart attacks</li><li>Hematological side effects like anemia, blockage of the arteries, blood clots in veins, anemia where the body doesn’t produce red blood cells, and thromboembolism</li><li>Immunological side effects like antibody development and immune system reactions to the drug</li><li>Neurological side effects like stroke, hypertensive encephalopathy (a disorder caused by malignant hypertension), seizures, and loss of blood flow to the brain</li><li>Respiratory side effects like <a href="http://www.mayoclinic.com/health/pulmonary-embolism/DS00429" target="_blank" rel="nofollow">pulmonary embolism</a>, or blockage of the arteries of the lungs</li><li>Other side effects like tumor progression</li></ul><h2>Common Adverse Side Effects</h2> This drug has more common and less severe adverse side effects to it, such as:<ul><li>Cardiovascular side effects like fluid accumulation (edema), chronic kidney disease and low blood pressure</li><li>Gastrointestinal side effects like abdominal pain</li><li>Respiratory side effects like cough and shortness of breath</li></ul></div><div class="v" id="tab2" ><h2 itemprop="aspect"> <strong> Warnings & Recalls for Darbepoetin Alpha </strong></h2><h1>Black Box Warning</h1> <b>Darbepoetin Alpha</b> has a “black box” warning associated with it that says that erythropoiesis-stimulating agents have the potential to increase death, heart attacks, stroke and other serious cardiovascular events.  Patients with chronic kidney failure at a heightened risk of death and serious ailments.  It also conveys that the lowest possible dosage of this drug should be administered at all times and treatment with <b>Darbepoetin Alpha</b> should be as minimal as possible.<h2>Contraindications</h2> The contraindications with <b>Darbepoetin Alpha</b> are as follows:<ul><li>Serious allergic reactions to the drug</li><li>Uncontrolled hypertension</li><li>Hypersensitivity to <b>Darbepoetin Alpha</b></li><li>Pure red blood cell aplasia that began with treatment with <b>Darbepoetin Alpha</b> or any other erythropoietin protein drug</li></ul><h2>Who Should Not Take This Drug</h2> The following preexisting conditions hinder a patient’s ability to take <b>Darbepoetin Alpha</b>.  These include:<ul><li>Cancer patients with anemia and who are receiving myelosuppressive chemotherapy when cure is the anticipated outcome</li><li>Chronic kidney disease patients with Hb greater than 11g/dL</li><li>Chronic kidney disease patients with insufficient Hb response to therapy</li><li>History of cardiac events</li><li>Failure to respond to or maintain a response</li><li>Patients undergoing hemodialysis</li><li>Hemoglobin increase in excess of 1g/dL within a 2 week period</li><li>Patients with latex allergies</li><li>Those who are taking lenalidomide</li></ul><h2>Pregnancy Warning</h2> This drug has been given a pregnancy category rating of “C” by the FDA, implying that although it doesn’t pose that much of a risk to the fetus, it probably is advisable to discontinue this drug after conception.</div><div class="v" id="tab3" ><h2 itemprop="aspect"> <strong> Darbepoetin Alpha Treatment and Use </strong></h2><div class="thumbnail-div"> <img width="84" height="84" src="http://www.bad-drug.net/wp-content/uploads/2013/01/Darbepoetin-Alpha-84x84.jpg?1df917" class="attachment-84x84 wp-post-image" alt="Darbepoetin Alpha" title="Darbepoetin Alpha" pagespeed_url_hash="1572360132" onload="pagespeed.CriticalImages.checkImageForCriticality(this);"/></div><p><b>Darbepoetin Alpha </b>is a synthetic form of <a target="_blank" href="http://en.wikipedia.org/wiki/Erythropoietin" target="_blank" rel="nofollow">erythropoietin</a>, an essential hormone that controls red blood cell production.  The brand name version of this drug is called <b><a target="_blank" href="http://www.bad-drug.net/bad-drug/aranesp" target="_blank" rel="nofollow">Aranesp</a>.</b>  This drug primarily treats <a href="http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001586/" target="_blank" rel="nofollow">anemia</a> which is associated with <a target="_blank" href="http://en.wikipedia.org/wiki/Chronic_kidney_disease" target="_blank" rel="nofollow">chronic renal failure</a> and <a target="_blank" href="http://en.wikipedia.org/wiki/Chemotherapy" target="_blank" rel="nofollow">chemotherapy</a>.  This drug was approved by the FDA on September of 2001 and comes in the form of an injection.</p><p><b>Darbepoetin Alpha</b> is reproduced by using <a target="_blank" href="http://www.britannica.com/EBchecked/topic/493667/recombinant-DNA-technology" target="_blank" rel="nofollow">recombinant DNA technology</a> by the modification of Chinese hamster ovary cells.</p><p>See the “Warnings and Recalls” tab to get more information about <b>Darbepoetin Alpha’s</b> “black box” warning.</p><h2>How This Drug Works</h2><p><b>Darbepoetin Alpha</b> is known as an <a target="_blank" href="http://en.wikipedia.org/wiki/Erythropoiesis" target="_blank" rel="nofollow">erythropoiesis</a> stimulating protein produced solely by recombinant DNA technology. This drug is related to the hormone that controls red blood cell production known as <a target="_blank" href="http://en.wikipedia.org/wiki/Erythropoietin" target="_blank" rel="nofollow">erythropoietin</a> and stimulates erythropoiesis by the same mechanism of action as both agents bind to stem cells, thereby stimulating the production of red blood cells.</p><h2>Dosage Information</h2><p>Recommended starting dose for chronic kidney disease patients on dialysis:</p><ul><li>0.45 mcg/kg intravenously or subcutaneously weekly, or</li><li>0.75 mcg/kg intravenously or subcutaneously every 2 weeks</li><li>Intravenous route is recommended for patients on hemodialysis</li></ul><p>Recommended starting dose for patients with chronic kidney disease not on dialysis:</p><ul><li>0.45 mcg/kg intravenously or subcutaneously at 4 week intervals</li></ul><p>Recommended starting dose for cancer patients on chemotherapy:</p><ul><li>2.25 mcg/kg subcutaneously weekly, or</li><li>500 mcg subcutaneously every 3 weeks</li></ul></div><div class="v" id="tab4" ><h2 itemprop="aspect"> Other Names for Darbepoetin Alpha</h2><h2>Brand Names</h2><br/><ul><br/><li>Aranesp</li><br/><li>Cresp</li><br/></ul><br/><h2>Generic Name</h2><br/><ul><br/><li>Darbepoetin Alpha</li><br/></ul></div><div class="v" id="tab5" ><h2 itemprop="aspect"> <strong> Lawsuits & Legal Information for Darbepoetin Alpha </strong></h2>